Sort   by:  
 Page size 
UnknownA 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Not available
S-EPMC5067625 | biostudies-literature
UnknownOral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
Not available
S-EPMC12865694 | biostudies-literature
UnknownDesign and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Not available
S-EPMC6889917 | biostudies-literature
UnknownTransforming jet flavour tagging at ATLAS.
Not available
S-EPMC12804921 | biostudies-literature
UnknownImpact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.
Not available
S-EPMC12824789 | biostudies-literature
UnknownObservation of quantum entanglement with top quarks at the ATLAS detector.
Not available
S-EPMC11410654 | biostudies-literature
UnknownFinerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Not available
S-EPMC9862372 | biostudies-literature
UnknownFinerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Not available
S-EPMC9271031 | biostudies-literature
UnknownDesign and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Not available
S-EPMC6888890 | biostudies-literature
UnknownOutcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Not available
S-EPMC10278789 | biostudies-literature
Sort   by:  
 Page size